ArticleAnnals of hematology2026
Predicting survival of Hodgkin lymphoma using machine learning-an analysis based on the SEER database.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to develop an effective model for predicting Hodgkin lymphoma (HL) prognosis as to assist clinicians in making optimal clinical decisions.
methodsThis study screened HL patients from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2021. Feature selection was performed using the Boruta algorithm. Four ML models were built based on the feature selection algorithm. The area under the curve (AUC), decision curve analysis, and Brier score were employed to evaluate the reliability of the four ML models. The feature importance was ranked through the Shapley Additive Explanation (SHAP). Based on the results of the SHAP plot, Kaplan-Meier analysis was used to compare the survival probabilities among different groups.
resultsAmong the 11,259 enrolled HL patients, 8,928 were alive and 2,331 had died. Primary site, year of diagnosis, B symptoms, surgery, marital status, Ann Arbor stage, radiation, SEER stage, chemotherapy, delay (diagnosis to treatment), age were associated with HL overall survival (OS). Of four ML models, the eXtreme Gradient Boosting (XGBoost) model exhibited superior predictive performance. For predicting 1-year OS, the net benefit of XGBoost, Cox proportional hazards (Coxph), and Random Survival Forest (RSF) models was significantly higher than that of the Light Gradient Boosting Machine (LightGBM) model, the treat-all model, and the treat-none model. Age, Ann Arbor stage, B symptoms, marital status, and radiation were the top five indicators in the feature importance ranking for HL OS.
conclusionThe XGBoost had excellent predictive performance in the prognostic model, which further helps clinicians to select appropriate treatment options.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.